Duration of humoral immunity to common viral and vaccine antigens
- PMID: 17989383
- DOI: 10.1056/NEJMoa066092
Duration of humoral immunity to common viral and vaccine antigens
Abstract
Background: Maintenance of long-term antibody responses is critical for protective immunity against many pathogens. However, the duration of humoral immunity and the role played by memory B cells remain poorly defined.
Methods: We performed a longitudinal analysis of antibody titers specific for viral antigens (vaccinia, measles, mumps, rubella, varicella-zoster virus, and Epstein-Barr virus) and nonreplicating antigens (tetanus and diphtheria) in 45 subjects for a period of up to 26 years. In addition, we measured antigen-specific memory B cells by means of limiting-dilution analysis, and we compared memory B-cell frequencies to their corresponding serum antibody levels.
Results: Antiviral antibody responses were remarkably stable, with half-lives ranging from an estimated 50 years for varicella-zoster virus to more than 200 years for other viruses such as measles and mumps. Antibody responses against tetanus and diphtheria antigens waned more quickly, with estimated half-lives of 11 years and 19 years, respectively. B-cell memory was long-lived, but there was no significant correlation between peripheral memory B-cell numbers and antibody levels for five of the eight antigens tested.
Conclusions: These studies provide quantitative analysis of serologic memory for multiple antigens in subjects followed longitudinally over the course of more than one decade. In cases in which multiple exposures or repeated vaccinations were common, memory B-cell numbers did not correlate with antibody titers. This finding suggests that peripheral memory B cells and antibody-secreting plasma cells may represent independently regulated cell populations and may play different roles in the maintenance of protective immunity.
Copyright 2007 Massachusetts Medical Society.
Similar articles
-
Correlation of Vaccine Responses.Front Immunol. 2021 Apr 2;12:646677. doi: 10.3389/fimmu.2021.646677. eCollection 2021. Front Immunol. 2021. PMID: 33868282 Free PMC article.
-
Antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study.BMC Immunol. 2014 Jun 21;15:26. doi: 10.1186/1471-2172-15-26. BMC Immunol. 2014. PMID: 24952415 Free PMC article.
-
Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines.Bone Marrow Transplant. 2001 Oct;28(7):681-7. doi: 10.1038/sj.bmt.1703228. Bone Marrow Transplant. 2001. PMID: 11704791
-
Antibody responses of healthy infants to concurrent administration of a bivalent haemophilus influenzae type b-hepatitis B vaccine with diphtheria-tetanus-pertussis, polio and measles-mumps-rubella vaccines.BioDrugs. 2001;15(6):413-8. doi: 10.2165/00063030-200115060-00007. BioDrugs. 2001. PMID: 11520252 Review.
-
Low intrathecal antibody production despite high seroprevalence of Epstein-Barr virus in multiple sclerosis: a review of the literature.J Neurol. 2018 Feb;265(2):239-252. doi: 10.1007/s00415-017-8656-z. Epub 2017 Nov 2. J Neurol. 2018. PMID: 29098417 Review.
Cited by
-
Serological responses to human virome define clinical outcomes of Italian patients infected with SARS-CoV-2.Int J Biol Sci. 2022 Sep 1;18(15):5591-5606. doi: 10.7150/ijbs.78002. eCollection 2022. Int J Biol Sci. 2022. PMID: 36263161 Free PMC article.
-
Anti-COVID-19 multi-epitope vaccine designs employing global viral genome sequences.PeerJ. 2020 Aug 3;8:e9541. doi: 10.7717/peerj.9541. eCollection 2020. PeerJ. 2020. PMID: 32832263 Free PMC article.
-
Advances in human B cell phenotypic profiling.Front Immunol. 2012 Oct 10;3:302. doi: 10.3389/fimmu.2012.00302. eCollection 2012. Front Immunol. 2012. PMID: 23087687 Free PMC article.
-
A review of clinical trials of human papillomavirus prophylactic vaccines.Vaccine. 2012 Nov 20;30 Suppl 5(0 5):F123-38. doi: 10.1016/j.vaccine.2012.04.108. Vaccine. 2012. PMID: 23199956 Free PMC article. Review.
-
Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.NPJ Vaccines. 2023 Nov 8;8(1):174. doi: 10.1038/s41541-023-00767-y. NPJ Vaccines. 2023. PMID: 37940656 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical